Amgen, Inc. revealed during its first quarter 2024 earnings call on 2 May that it will focus its research and development investment in obesity going forward largely on MariTide (maridebart cafraglutide, AMG 133) after a look at interim Phase II results for the GIP receptor antagonist/GLP-1 agonist and the completion of a Phase I trial for the obesity candidate AMG 786. Planning is under way for a multi-indication Phase III MariTide program, but development of AMG 786 is discontinued.
Amgen Planning Pivotal Obesity Program For MariTide
MariTide Phase III Trials To Include Diabetes
Executives said during Amgen’s Q1 call that the company is “encouraged” by interim Phase II data for MariTide (AMG 133) in obesity, so it is designing Phase III trials and building manufacturing capacity.
More from Alimentary/Metabolic
More from Therapy Areas
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.